In a Phase II trial in melanoma patients, tunlametinib demonstrated an overall response rate of 35.8%. Credit: Africa Studio / Shutterstock.com.

The China National Medical Products Administration (NMPA) has approved KeChow Pharma’s tunlametinib (HL-085) for treating patients with neuroblastoma ras viral oncogene homolog (NRAS) mutated advanced melanoma.

Tunlametinib, a mitogen-activated protein kinase (MEK) inhibitor, becomes the first targeted therapy approved for this group of patients.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

It is also the first product developed in-house by KeChow since its establishment.

The Center for Drug Evaluation of the NMPA had previously granted a priority review for the company’s new drug application for tunlametinib.

The decision for approval is based on the outcomes of a multicentre, single-arm Phase II registrational clinical trial in China involving 100 patients.

Tunlametinib’s clinical efficacy data demonstrated an overall response rate (ORR) of 35.8%, median progression-free survival of 4.2 months, and a disease control rate of 72.6%.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Further subgroup analysis revealed that subjects who had previously undergone immunotherapy had an ORR of 40.6%.

Rash was the most frequently observed treatment-related skin event while the most common severe treatment-related adverse event was a rise in blood creatine phosphokinase.

Tunlametinib showed enhanced pharmacokinetic characteristics and greater target inhibition versus other licensed MEK inhibitors.

KeChow founder, CEO and chairman Dr Hongqi Tian stated: “Tunlametinib, approved in China, is the first internally designed and developed molecule by the KeChow team.

“The approval of tunlametinib is an important milestone to provide new treatment options for Chinese patients with NRAS-mutated advanced melanoma who previously received PD-1/PD-L1.

“We would like to express our sincere gratitude to the clinicians and patients who participated in our trials, and we thank the health authorities for their strong support. We are committed to making tunlametinib available in China as soon as possible to serve this patient population.”